Since Doug Williams signed on as Executive Vice President of Research and Development at Biogen Idec in 2011, the company has had a string of successes. Its oral multiple sclerosis drug Tecfidera has snagged a spot as one of the best launches ever, with well over US$1 billion in its first full four quarters of sales, and a recent pair of long-acting haemophilia drug approvals are set to shake up the haematology market. Future growth could come from remyelinating agents, Alzheimer's disease drugs and gene therapy, Williams tells Asher Mullard.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Doug Williams. Nat Rev Drug Discov 13, 880–881 (2014). https://doi.org/10.1038/nrd4496
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd4496
